Amazon’s One Medical launches integrated, physician‑led GLP‑1 weight‑management program
- Amazon said on April 21 that One Medical has launched a nationwide GLP-1 management program, tying weight-loss prescribing to its primary care clinics, virtual follow-ups, and Amazon Pharmacy fulfillment. - Amazon said insured patients can pay as little as $25 a month for GLP-1 drugs, while cash prices start at $149 for pills, $299 for injectables, and renewals at $29. - The push folds obesity care into routine medicine as demand surges for Wegovy and Zepbound and more than 2 in 5 U.S. adults have obesity. (cdc.gov)
Amazon’s One Medical has launched a nationwide GLP-1 weight-management program that routes obesity treatment through primary care instead of a stand-alone telehealth prescription. (cnbc.com) (health.amazon.com) The program combines in-person and virtual visits, ongoing follow-ups, prescription management, and pharmacy fulfillment through Amazon Pharmacy. Amazon said patients can start through a One Medical clinician and continue treatment with structured support over time. (health.amazon.com) (fiercehealthcare.com) GLP-1 drugs mimic a hormone involved in appetite and blood-sugar control, which is why they are used for chronic weight management as well as diabetes in some cases. On its program page, Amazon lists injectable options including Wegovy and Zepbound and oral options including Wegovy and orforglipron, with eligibility determined by a licensed provider. (health.amazon.com) Amazon said insured pricing can start as low as $25 a month. For cash-paying patients, it said oral medicines start at $149 a month, injectable treatments start at $299 a month, message-based renewals start at $29, and video renewals start at $49. (cnbc.com) The company is pitching the service as long-term obesity care, not a one-time prescription. Amazon said the model is meant to let clinicians track side effects, adjust treatment, and manage related conditions inside the same primary care relationship. (publicnow.com) (drugstorenews.com) That approach targets a problem that has grown with the boom in weight-loss drugs: patients can get access quickly, but follow-up care is often fragmented. Health-care trade publications described Amazon’s move as an attempt to connect prescribing, monitoring, and delivery in one workflow. (healthcaredive.com) (fiercehealthcare.com) The market noticed. CNBC reported shares of Hims & Hers Health, Viking Therapeutics, Amgen, and Septerna fell after Amazon’s announcement as investors weighed a larger retail competitor entering obesity care. (cnbc.com) Amazon is entering a category with enormous demand and a large disease burden. The Centers for Disease Control and Prevention says more than 2 in 5 U.S. adults have obesity, which accounted for nearly $173 billion in medical expenditures in 2019 dollars. (cdc.gov) The closing bet is simple: if Amazon can turn GLP-1 treatment into a bundled primary-care service with pharmacy delivery, it can sell convenience as much as medicine. (cnbc.com) (health.amazon.com)
